Akihiko Shimono

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance

M. Nangaku, Y. Miyakawa, M. Mizuno, 2018, Clinical and Experimental Nephrology.

Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan

Y. Kanda, T. Ikezoe, Y. Kanakura, 2022, International Journal of Hematology.

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance

M. Nangaku, Y. Miyakawa, M. Mizuno, 2018, Clinical and Experimental Nephrology.

Comparison of outcomes after plasma therapy or eculizumab in pediatric patients with atypical hemolytic uremic syndrome

A. Ashida, Y. Fujii, Akihiko Shimono, 2022, Clinical and Experimental Nephrology.

Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan

S. Ito, S. Kagami, M. Ogura, 2022, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Application of a scoring system in Japanese patients diagnosed with atypical hemolytic uremic syndrome to assess the relationship between the score and clinical responses to eculizumab

S. Maruyama, Noritoshi Kato, M. Matsumoto, 2023, Thrombosis Journal.

Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan

S. Maruyama, T. Nakano, T. Kawaguchi, 2023, International Journal of Hematology.

Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan

Y. Kanda, A. Gotoh, T. Ikezoe, 2023, International Journal of Hematology.